Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Effectiveness of amino acid supplementation in preventing acute kidney injury following cardiac surgery: A systematic review and meta-analysis of randomized controlled trials.

  • 2025-05-23
  • Acta anaesthesiologica Scandinavica 69(6)
    • Mir Wajid Majeed
    • Emma Finnegan
    • Mariano Gallo Ruelas
    • Lucca Moreira Lopes
    • Bruno Branco Righetto
    • Issa Salha
    • Daniel Delgado
    • Melissa Chacón Quirós
    • Assaina Tatiana Jaquissone Tomo
    • Raheel Ahmad
    • Suhaib Andrabi
    • Samer Abujaber

Study Design

Type
Meta-Analysis
Population
4501 cardiac surgery patients
Methods
Systematic review and meta-analysis of RCTs; PubMed, Embase, and Cochrane databases searched for RCTs comparing AA supplementation versus standard care in preventing cardiac surgery-associated AKI.

Introduction

Acute kidney injury (AKI) is a frequent complication of cardiac surgery, contributing to increased morbidity, longer hospital stays, and higher mortality. Evidence suggests amino acid (AA) supplementation may enhance renal blood flow and glomerular filtration rate (GFR), potentially reducing AKI risk; however, findings remain inconclusive. This study evaluated the efficacy of perioperative AA supplementation in preventing AKI and related complications post-cardiac surgery.

Methods

PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs) comparing AA supplementation versus standard care in preventing cardiac surgery-associated AKI. Main outcomes included AKI incidence (defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria), 30-day mortality, and renal replacement therapy (RRT) requirement. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Statistical significance was set at p < 0.05. The certainty of the evidence (CoE) was assessed using the GRADE approach.

Results

Six RCTs involving 4501 cardiac surgery patients were included. AA mixture interventions significantly reduced the risk of AKI stage 1 (RR: 0.56; 95% CI: 0.77-0.96; p = .009; CoE: Moderate) and Stage 3 (RR: 0.53; 95% CI: 0.34-0.83; p = .005; CoE: Moderate), but not stage 2 (RR: 1.24; 95% CI: 0.60-2.55; p = .568; CoE: Low). Preliminary findings from glutamic acid and glutamine (single AA interventions) showed potential benefits in reducing AKI incidence (CoE: Very low) and improving surrogate biomarkers, respectively. No significant effects were observed on mortality or RRT incidence for any intervention.

Conclusion

AA mixtures likely reduce AKI incidence following cardiac surgery but show limited effects on mortality and RRT. Further trials are needed to confirm the benefits of glutamic acid and glutamine supplementation.

Editorial comment

Use of amino acid supplementation for the prevention of acute kidney injury after cardiac surgery may be effective, but more trial data and confidence in a beneficial effect is needed for this to be implemented in everyday clinical practice.

Research Insights

  • L-Glutamic Acid→Reduced Acute Kidney Injury Incidence

    Preliminary findings from glutamic acid and glutamine (single AA interventions) showed potential benefits in reducing AKI incidence (CoE: Very low) and improving surrogate biomarkers, respectively.

    Effect
    Neutral
    Effect size
    Small
  • L-Glutamine→Reduced Acute Kidney Injury Incidence

    Preliminary findings from glutamic acid and glutamine (single AA interventions) showed potential benefits in reducing AKI incidence (CoE: Very low) and improving surrogate biomarkers, respectively.

    Effect
    Neutral
    Effect size
    Small
Back to top